सेलेकॉक्सिब और सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम का इंटरैक्शन

• In patients who have demonstrated allergic-type reactions to sulfonamides [ see Warnings and Precautions (5.7) ].

• Known hypersensitivity to celecoxib, or any components of the drug product or sulfonamides.

Celecoxib is a sulfonamide and both NSAIDs and sulfonamides may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people [ see Contraindications (4) and Warnings and Precautions (5.8) ].

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib.

A dosage adjustment may be warranted when VYSCOXA is administered with CYP2C9 inhibitors or inducers [ see Clinical Pharmacology (12.3) ].